Lonza Group Ag (LZAGY) could be a solid choice for investors given its recent upgrade to a Zacks Rank #2 (Buy). This upgrade primarily reflects an upward trend in earnings estimates, which is one of ...

How Lonza Capsules & Health Ingredients (CHI) is redefining drug delivery with cutting-edge capsule innovation, ...

Swiss Contract Service Provider Lonza Exits Capsules Business To Focus On Drug Development Lonza unveils its "One Lonza" strategy, highlighting a new structure to streamline operations ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

In a report released today, Charles Pitman CFA from Barclays maintained a Buy rating on Lonza Group Ltd (LONN – Research Report), with a price ...

Lonza Group AG's (VTX:LONN) earnings announcement last week didn't impress shareholders. Despite the soft profit numbers, our analysis has optimistic about the overall quality of the income statement.

Barclays analyst Charles Pitman lowered the firm’s price target on Lonza (LZAGY) to CHF 670 from CHF 710 and keeps an Overweight rating on the ...

Lonza will serve as a CMAC Translation to Industry Collaborator, reinforcing its commitment to advancing innovative ...